Memantine
Treatment for Vascular Dementia
Typical Dosage: 5-20 mg daily
Effectiveness
60%
Safety Score
65%
Clinical Trials
4
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
5-20 mg daily
Time to Effect
1-3 months
Treatment Duration
Lifetime
Evidence Quality
MODERATENumber Needed to Treat (NNT)
18(Treat 18 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
50(Treat 50 patients to see 1 additional serious adverse event)
Confidence Score
65%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$150
Monitoring:$500
Side Effect Mgmt:$50
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$70,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$2,333
Memantine Outcomes
for Vascular Dementia
Efficacy Outcomes
Overall Effectiveness
+60%
Response Rate
+30%
Common Side Effects
Dizziness
+6%
Headache
+5%
Confusion
+5%
Constipation
+4%
Sources:
Active Clinical Trials
1 active trial recruiting for Memantine in Vascular Dementia
Efficacy, Safety and Response Predictors of Adjuvant Astragalus for Cognition in Orthostatic Hypotension
NCT05647473RECRUITINGPHASE2
66 participants
INTERVENTIONAL
Fuzhou, China
Started: Feb 20, 2024
Completed Clinical Trials
3 completed trials for Memantine in Vascular Dementia
Local Study of Akatinol Memantine in VaD in Russia
NCT03986424COMPLETEDPHASE3
130 participants
INTERVENTIONAL
Moscow, Russia +3 more
Started: Jan 23, 2018
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE
NCT02860338COMPLETED
900 participants
OBSERVATIONAL
Started: Jan 1, 2009
Masitinib in Patients With Mild to Moderate Alzheimer's Disease
NCT01872598COMPLETEDPHASE3
721 participants
INTERVENTIONAL
Varna, Bulgaria +5 more
Started: Jan 1, 2012